Neurocrine Biosciences (NBIX) Inventory Average (2017 - 2026)

Neurocrine Biosciences' Inventory Average history runs 10 years deep, the most recent figure standing at $66.8 million for Q1 2026.

• Quarterly Inventory Average rose 14.59% year-over-year to $66.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.8 million (up 14.59% YoY) and the FY2025 annual result came in at $63.2 million, up 32.08% from the prior year.
• Inventory Average was $66.8 million for Q1 2026 at Neurocrine Biosciences, down from $69.1 million in the prior quarter.
• Across five years, Inventory Average topped out at $69.1 million in Q4 2025 and bottomed at $29.2 million in Q2 2022.
• A 5-year average of $44.0 million and a median of $37.8 million in 2024 frame the typical range for Inventory Average.
• Annual changes were most pronounced in 2023 — Inventory Average retreated 8.75% — and 2025, when it surged 54.3%.
• Neurocrine Biosciences' Inventory Average stood at $36.0 million in 2022, then slipped by 6.93% to $33.6 million in 2023, then soared by 53.8% to $51.6 million in 2024, then surged by 34.01% to $69.1 million in 2025, then decreased by 3.47% to $66.8 million in 2026.
• Business Quant data shows NBIX's Inventory Average at $66.8 million in Q1 2026, $69.1 million in Q4 2025, and $63.1 million in Q3 2025.